tradingkey.logo

Becton Dickinson and Co

BDX
View Detailed Chart
201.090USD
-0.830-0.41%
Close 01/29, 16:00ETQuotes delayed by 15 min
57.39BMarket Cap
34.47P/E TTM

Becton Dickinson and Co

201.090
-0.830-0.41%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.41%

5 Days

-2.40%

1 Month

+3.04%

6 Months

+10.26%

Year to Date

+3.62%

1 Year

-18.55%

View Detailed Chart

Key Insights

Becton Dickinson and Co's fundamentals are relatively healthy, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 12 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 208.21.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Becton Dickinson and Co's Score

Industry at a Glance

Industry Ranking
12 / 205
Overall Ranking
74 / 4540
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Becton Dickinson and Co Highlights

StrengthsRisks
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 21.84B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 71.28%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 71.28%.
Undervalued
The company’s latest PE is 34.61, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 268.89M shares, increasing 0.03% quarter-over-quarter.
Held by Ray Dalio
Star Investor Ray Dalio holds 9.50K shares of this stock.

Analyst Rating

Based on 14 analysts
Buy
Current Rating
208.213
Target Price
+3.18%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Becton Dickinson and Co News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Becton Dickinson and Co Info

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
Ticker SymbolBDX
CompanyBecton Dickinson and Co
CEOPolen (Thomas E)
Websitehttps://www.bd.com/
KeyAI